At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 356 enrolled
Drug / intervention
rhPSMA-7.3 (18F) Injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer
In Brief
A Phase 3 clinical trial evaluating rhPSMA-7.3 (18F) Injection and Positron Emission Tomography scan for Prostate Cancer. Completed, enrolled 356 participants across 34 sites in 4 countries.
Detailed Summary
A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFinland, Germany, Netherlands, United States
CollaboratorsParexel
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartMar 2020
Primary CompletionJun 2021
TodayJul 2026
First PostedDec 5, 2019
Enrollment StartMar 2, 2020
Primary CompletionJun 21, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.6 years ago
Interventions
rhPSMA-7.3 (18F) Injectiondrug
Radioligand for PET CT scanning
Positron Emission Tomography scanother
imaging test with radioligand